Ambroxol Hydrochloride

證據等級: L5

預測適應症: 0 個

AMBROXOL HYDROCHLORIDE: Evaluation Incomplete — No Repurposing Predictions Available

One-Sentence Summary

Ambroxol Hydrochloride is a mucolytic agent widely used to treat respiratory tract disorders involving excessive mucus production, such as bronchitis and COPD. The TxGNN model did not return any predicted new indications for this drug in the current run, and the evidence pack is missing key data required for a complete repurposing evaluation — including mechanism of action, safety warnings, and Singapore regulatory records.

Quick Overview

Item	Content
Original Indication	Not available in current data pack
Predicted New Indication	No predictions returned
TxGNN Prediction Score	N/A
Evidence Level	N/A — No predictions to evaluate
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Safety Considerations

Please refer to the package insert for safety information.

No drug interaction data was found in the DDI query. Key warnings and contraindications were not available in this evidence pack. Please consult the official prescribing information before clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline returned zero predicted indications for Ambroxol Hydrochloride, and the evidence pack contains two blocking data gaps — the Singapore (HSA) prescribing information and mechanism of action — which prevent even a baseline safety and mechanistic assessment. No evaluation can proceed without these inputs.

To proceed, the following is needed:

Predicted indications from TxGNN: Re-run the KG + DL prediction pipeline with AMBROXOL HYDROCHLORIDE mapped to its correct DrugBank ID (DB06742). Verify that the drug node exists in data/node.csv and that mappings in drugbank_mapper.py cover the hydrochloride salt form.
DrugBank ID confirmation: The drugbank_id field is null. Confirm the correct ID (likely DB06742 for ambroxol) and re-query DrugBank for MOA, categories, and toxicity data.
Singapore HSA package insert: Download the prescribing information PDF from the HSA product listing to extract approved indications, key warnings, and contraindications (Data Gap DG001).
Singapore market registration check: Ambroxol is available in many Asian markets; verify whether it is registered under a different INN spelling, brand name, or combination product (e.g., ambroxol + other agents) in the HSA database before confirming "Not marketed" status.
MOA data (Data Gap DG002): Retrieve mechanism of action from DrugBank or ChEMBL to enable mechanistic plausibility analysis for any future predictions.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.